*EMBARGOED All research presented at the 2022 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Sunday, October 23, 2022, at 12:00 pm EDT.
Sunday, October 23, 2022 | 5:00 PM – 7:00 PM ET | Location: Crown Ballroom
Author Insight from Khaled Alsabbagh Alchirazi, MD, Cleveland Clinic
What’s new here and important for clinicians?
In a large USA cohort of patients with inflammatory bowel disease (IBD), we found a significant difference in medication treatment between Black and white patients. The Black patients were less likely to be treated with immunomodulators or biologic therapies. Although there may be differences in disease presentation that our study could not identify, e.g. milder IBD in Black patients, there appears to be a disparity in the utilization of advanced therapies. More studies are needed to understand the factors that contribute to healthcare disparity in IBD medication utilization.
What do patients need to know?
Inflammatory bowel disease (IBD) is a chronic gastrointestinal disease that often requires immunomodulators and/or biologics to achieve remission.
IBD that is not properly treated and managed can lead to serious complications. To optimize the treatment of IBD, it is best when patients and providers practice shared-decision making and develop a trust-based relationship.
Author Contact
Khaled Alsabbagh Alchirazi, MD (First Author) & Miguel Regueiro, MD (Senior Author), Cleveland Clinic
Khaled.alsabb [at] gmail.com
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi.org or by phone at 301-263-9000.